Observational studyJournal of pediatric gastroenterology and nutrition2026
Serum aspartate aminotransferase to platelet ratio index in relation to liver histopathology of biliary atresia.
Observational study in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo investigate the prognostic significance of aspartate aminotransferase to platelet ratio index (APRI) in relation to histopathological features across the clinical course of biliary atresia (BA).
methodsIn this observational cohort study, we enrolled 135 BA patients with available APRI values at Kasai portoenterostomy (KPE, n = 116) or at post-KPE follow-up (n = 70; serum samples, n = 139; liver biopsies, n = 139). APRI was matched to manual scorings of liver histology, ductular reaction (DR) analysed using neural network model and fibrosis quantified from Sirius Red-stained sections.
resultsAPRI was elevated at both KPE and post-KPE follow-up (0.92 vs. 1.2, p = 0.5), and associated with biochemical markers of cholestasis, and decreased liver function. At KPE, APRI was higher in patients failing to resolve cholestasis postoperatively (0.80 vs. 0.96, p = 0.02) and both at KPE (0.77 vs. 0.94, p = 0.06) and post-KPE (0.7 vs. 2.1, p < 0.001) in those with subsequent need for liver transplant (LT). Across the disease course, APRI moderately predicted LT need (at KPE, HR = 1.4, p = 0.01; post-KPE, HR = 1.2, p < 0.001). APRI correlated with DR (at KPE, R = 0.37, p < 0.001; post-KPE, R = 0.35, p < 0.001), composed of biliary epithelium (R = 0.34, p < 0.001; R = 0.25, p < 0.01) and parenchymal intermediate hepatocytes (R = 0.33, p < 0.001; R = 0.43, p < 0.001) during the entire clinical course. APRI showed no correlation with quantified liver fibrosis at KPE (R = 0.16, p = 0.13), but correlated with quantified fibrosis (R = 0.22, p = 0.02) and Metavir staging (R = 0.46, p < 0.001) after KPE. No association was observed with portal inflammatory cell infiltration or histological cholestasis.
conclusionsAPRI reflects biliary and portal injury rather than generalised liver fibrosis and associates with poor prognosis in BA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.